SCHEMBL4604187

SCHEMBL4604187

O=C(O)c1cc(OCc2ccccc2C(F)(F)F)ccc1NC(=O)C1CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.52
HSD17B10 Q99714 1/20 0.52
MAOB P27338 3/20 0.48
MAOA P21397 1/20 0.48
POLB P06746 1/20 0.46
RBP4 P02753 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ADAM17 P78536 2/20 0.44
MAPT P10636 1/20 0.44
MMP1 P03956 1/20 0.44
ADAMTS4 O75173 2/20 0.43
MMP13 P45452 2/20 0.43
PLG P00747 1/20 0.43
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827641 0.89 KDM4E (0.51) KDM4EHSD17B10RXFP1
SCHEMBL1826748 0.88 KDM4E (0.50) KDM4EHSD17B10RBP4CYP3A4CYP2C9
SCHEMBL1825088 0.87 KDM4E (0.49) KDM4EHSD17B10RBP4CYP3A4CYP2C9
SCHEMBL1825885 0.87 KDM4E (0.49) KDM4EHSD17B10RBP4CYP3A4CYP2C9
SCHEMBL4604582 0.85 MAOB (0.53) KDM4EHSD17B10MAOBMAOARBP4
SCHEMBL1827185 0.84 KDM4E (0.50) KDM4EHSD17B10POLB
SCHEMBL4603406 0.83 GAA (0.53) KDM4EHSD17B10POLBRBP4CYP3A4
SCHEMBL1825725 0.82 KDM4E (0.47) KDM4EHSD17B10POLBRXFP1
SCHEMBL1826827 0.82 KDM4E (0.50) KDM4EHSD17B10RXFP1
SCHEMBL1824147 0.82 KDM4E (0.47) KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN claimed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP claimed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN claimed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US claimed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US claimed
US-20210379070-A1 MALONATE SALT OF VARLITINIB ASLAN PHARMACEUTICALS PTE LTD (SG) 2021-12-09 US disclosed
US-10646478-B2 Methods for treatment of melanoma CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-05-12 US disclosed
US-10016402-B2 Methods for treatment of melanoma CHILDREN'S MEDICAL CENTER CORPORATION (US) 2018-07-10 US disclosed
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10646478-B2 Methods for treatment of melanoma DHODH, ALDH1A2, DLD KDM4E 570/4885HSD17B10 261/4885MAOB 144/4885
US-20210379070-A1 MALONATE SALT OF VARLITINIB KRAS, JAK1, JAK2 KDM4E 663/4885HSD17B10 3268/4885MAOB 4700/4885
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 KDM4E 2898/4885HSD17B10 783/4885MAOB 1445/4885
US-10016402-B2 Methods for treatment of melanoma DHODH, ALDH1A2, DLD KDM4E 570/4885HSD17B10 261/4885MAOB 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.